Of baseball and enhancement bondage
By Pete Shanks,
San Francisco Chronicle
| 09. 26. 2005
Baseball fans around the nation have been conducting their own straw poll about human enhancement, and they don't like it. Rafael Palmeiro has practically been driven out of the game, Mark McGwire is now seen as more cartoon than hero, and Jason Giambi is treated with widespread derision.
Then there is Barry Bonds.
Bonds is -- as usual -- a lightning rod for everyone's feelings, a walking paradox who illustrates without even trying just how complex these issues are. He told reporters before his first game in Washington, D.C., that there are more serious issues than steroids, but all that did was increase the hype about his appearance. And he lived up to it.
Bonds getting booed is not unusual in a road game. But in Washington, he was booed by fans who were on their feet as he homered to the upper deck -- clapping at the same time they were jeering. Whether they were right or wrong about Bonds (who denies ever knowingly taking illegal substances), there couldn't be a more dramatic illustration of the conflicts we feel...
Related Articles
By Mariella Bodemeier Loayza Careaga, The Scientist | 03.15.2024
Scientists have genetically modified isolated microbes for decades. Now, using CRISPR, they intend to target entire microbiomes.
Humans are never alone. Even in a room devoid of other people, they are always in the company of billions of microscopic beings...
By Gerry Smith, Bloomberg | 03.12.2024
When Celenise Mahmood first learned about two new gene therapies that could cure sickle cell disease, she felt a wave of relief.
Her 9-year-old son, Navid, has the inherited blood disorder. By age 5, he’d had over 30 life-saving blood...
By Carol Cardona and Michelle Kromm, Scientific American | 03.11.2024
By Nada Hassanein, New Jersey Monitor | 03.14.2024
The U.S. Food and Drug Administration late last year approved two breakthrough gene therapies for sickle cell disease patients. Now a new federal program seeks to make these life-changing treatments available to patients with low incomes — and it could...